AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9166373 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies for multiple sclerosis management, specific therapies not detailed, duration not specified.
Number of subjects: 0
Study 8319063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of a negative oral contrast agent (oral magnetic particles) administered in 800 ml of a viscous suspension
Number of subjects: 40
Study 8319063 — intervention group
Group type: COMPARATOR
Intervention: Pre-contrast MRI series
Number of subjects: 40
Study 3565937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (15 min)
Number of subjects: 17
Study 3565937 — intervention group
Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 17
Study 31425479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1136
Study 31425479 — intervention group
Group type: COMPARATOR
Intervention: Non-ipilimumab control treatments
Number of subjects: 1136
Study 30277862 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept (320 mg loading dose at day 0, then 160 mg for 5 subsequent weekly doses)
Number of subjects: 19
Study 30277862 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 19
Study 30277862 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 26882015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafuramidine (100 mg orally twice a day for 10 days)
Number of subjects: 273
Study 26882015 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine (4 mg/kg intramuscularly once daily for 7 days)
Number of subjects: 273
Study 26882015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafuramidine
Number of subjects: 273
Study 26882015 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 273
Study 24993817 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol DPI (children: 200 μg/24 μg, adolescents/adults: 400 μg/24 μg)
Number of subjects: 85
Study 24993817 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol DPI (adolescents/adults: 400 μg/24 μg)
Number of subjects: 85
Study 24993817 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization for BDP/formoterol dose
Number of subjects: 85
Study 21737312 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention to foster optimal antiretroviral treatment-taking behavior
Number of subjects: 51
Study 21737312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 19568773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant triple-therapy regimen (aprepitant, ondansetron, and dexamethasone)
Number of subjects: 848
Study 19568773 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (ondansetron and dexamethasone)
Number of subjects: 848
Study 18192791 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 18192791 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides (including azithromycin)
Number of subjects: 0
Study 18192791 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 16444998 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 21
Study 16444998 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (DIP)
Number of subjects: 21
Study 12578455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (0.5‐mg/mL) applied to the rhinostomy site for 5 minutes during surgery
Number of subjects: 155
Study 12578455 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic sodium chloride solution) applied to the rhinostomy site for 5 minutes during surgery
Number of subjects: 155
Study 11194594 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR + consistent atrial pacing mode
Number of subjects: 15
Study 11194594 — intervention group
Group type: COMPARATOR
Intervention: DDDR
Number of subjects: 15
Study 8639069 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dihydroergotamine mesylate (1 mg)
Number of subjects: 295
Study 8639069 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan succinate (6 mg)
Number of subjects: 295
Study 2062512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early photocoagulation (scatter and focal treatment)
Number of subjects: 3711
Study 2062512 — intervention group
Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 3711
Study 2062512 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal photocoagulation
Number of subjects: 3711
Study 2062512 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatter photocoagulation
Number of subjects: 3711
Study 2062512 — intervention group
Group type: EXPERIMENTAL
Intervention: Less extensive scatter photocoagulation
Number of subjects: 3711
Study 6852359 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (750 mg/day in three divided doses at meals)
Number of subjects: 20
Study 6852359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29728286 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity Program (120 min/week with sociocultural activities once a month)
Number of subjects: 364
Study 29728286 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity Program
Number of subjects: 364
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) concentrations in patients with Gram-negative bacteremia
Number of subjects: 6561
Study 29753321 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) concentrations in patients with Gram-positive bacteremia or candidemia
Number of subjects: 6561
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve analysis for prediction of Gram-negative bacteremia
Number of subjects: 6561
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized cutoff value for PCT
Number of subjects: 6561
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT concentrations in relation to specific pathogens
Number of subjects: 6561
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT concentrations in relation to foci of infection
Number of subjects: 6561
Study 29753321 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model for PCT values
Number of subjects: 6561
Study 26297598 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Dudes program with tangible prizes
Number of subjects: 2292
Study 26297598 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Dudes program with teacher praise
Number of subjects: 2292
Study 26297598 — intervention group
Group type: COMPARATOR
Intervention: Food Dudes program (both prize and praise)
Number of subjects: 2292
Study 25475460 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy after fibrinolysis
Number of subjects: 992
Study 22269820 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cisatracurium (0.78 ± 0.15 μg.kg(‐1).min(‐1))
Number of subjects: 30
Study 22269820 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus injection of cisatracurium (1.09 ± 0.33 μg.kg(‐1).min(‐1))
Number of subjects: 30
Study 22269820 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cisatracurium
Number of subjects: 30
Study 22269820 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus injection of cisatracurium
Number of subjects: 30
Study 22269820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20578382 — intervention group
Group type: EXPERIMENTAL
Intervention: Single usage of acupoints of Shaoyang meridian (Fengchi (GB 20), Yifeng (TE 17), Wangu (GB 12) at the affected side) from the 3rd day to the 14th day, followed by routine acupoints (Hegu (LI 4) on both sides, Fengchi (GB 20), Quchi (LI 11), Yangbai (GB 14) at the affected side) after the 15th day, along with oral Prednisone.
Number of subjects: 120
Study 20578382 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoints (same as the routine ones in the observation group) from the 3rd day, along with oral Prednisone.
Number of subjects: 120
Study 17567417 — intervention group
Group type: EXPERIMENTAL
Intervention: New antenatal care model (five-visit model)
Number of subjects: 13517
Study 17567417 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care model
Number of subjects: 13517
Study 15597183 — intervention group
Group type: EXPERIMENTAL
Intervention: Precue condition (arrows indicating target locations before the array)
Number of subjects: 0
Study 15597183 — intervention group
Group type: EXPERIMENTAL
Intervention: Simcue condition (arrows indicating target locations simultaneously with the array)
Number of subjects: 0
Study 15597183 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcue condition (arrows indicating target locations after the array)
Number of subjects: 0
Study 15597183 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG potentials recorded during the experiment
Number of subjects: 0
Study 11886903 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-trap traction
Number of subjects: 223
Study 11886903 — intervention group
Group type: COMPARATOR
Intervention: Manual manipulation
Number of subjects: 223
Study 9475655 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact loading variables (three impact velocities and three interface materials)
Number of subjects: 19
Study 8529329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous losartan
Number of subjects: 18
Study 8529329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous EXP3174
Number of subjects: 18
Study 8529329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral losartan
Number of subjects: 18
Study 8529329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral EXP3174
Number of subjects: 18
Study 2193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Number of subjects: 57
Study 2193518 — intervention group
Group type: COMPARATOR
Intervention: Pelvic examination
Number of subjects: 57
Study 6305113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation with a total dose of 25.5 Gy in fractions of 5.1 Gy daily for 5 days
Number of subjects: 58
Study 6305113 — intervention group
Group type: COMPARATOR
Intervention: Retrospective data from 1976 to 1979 for patients operated upon for 'local cure'
Number of subjects: 58
Study 30347485 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood overweight/obesity (Metabolic Groups III and IV)
Number of subjects: 2020
Study 30347485 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass index in adulthood (after childhood overweight/obesity)
Number of subjects: 2020
Study 30347485 — intervention group
Group type: COMPARATOR
Intervention: Childhood normal body mass index (Metabolic Groups I and II)
Number of subjects: 2020
Study 27822727 — intervention group
Group type: EXPERIMENTAL
Intervention: Handcrafted vacuum‐assisted therapy (changed every 72 hours)
Number of subjects: 126
Study 27822727 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (debridement and cure with soap every 24 hours)
Number of subjects: 126
Study 27711190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 881
Study 23932021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 28 sessions at a partial pressure of oxygen of 240 kPa for 90 min
Number of subjects: 22
Study 23932021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 22
Study 21748755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 25 mg of lenalidomide
Number of subjects: 0
Study 19852807 — intervention group
Group type: COMPARATOR
Intervention: Normal gait (control group)
Number of subjects: 20
Study 19852807 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic gait (intervention group)
Number of subjects: 20
Study 17606973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 32 mg/m² 3-hour infusion (arm A)
Number of subjects: 146
Study 17606973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 6 mg/m² 1-hour infusion daily for 5 consecutive days (arm B)
Number of subjects: 146
Study 16939989 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 49
Study 16939989 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroid add-on
Number of subjects: 49
Study 16939989 — intervention group
Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 49
Study 12923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training course
Number of subjects: 160
Study 12923800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 160
Study 10821130 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus amlodipine (group II, n=13)
Number of subjects: 30
Study 10821130 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor alone (group I, n=17)
Number of subjects: 30
Study 8604670 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet
Number of subjects: 7
Study 8604670 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 7
Study 2004543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2000 mg daily for 10 days
Number of subjects: 218
Study 6824134 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous autotransfused blood
Number of subjects: 50
Study 6824134 — intervention group
Group type: COMPARATOR
Intervention: Bank blood
Number of subjects: 50
Study 6824134 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvaged autologous blood
Number of subjects: 50
Study 6824134 — intervention group
Group type: COMPARATOR
Intervention: Control group (unshed autologous blood)
Number of subjects: 50
Study 6824134 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function values and free hemoglobin levels
Number of subjects: 50
Study 29164599 — intervention group
Group type: EXPERIMENTAL
Intervention: JWH‐018 2 mg
Number of subjects: 6
Study 29164599 — intervention group
Group type: EXPERIMENTAL
Intervention: JWH‐018 3 mg
Number of subjects: 6
Study 29164599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28790354 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 101
Study 26136534 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g whey protein (PRO) postexercise
Number of subjects: 15
Study 26136534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) postexercise
Number of subjects: 15
Study 23032867 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐ICD (subcutaneous implantable cardioverter-defibrillator)
Number of subjects: 69
Study 23032867 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICD
Number of subjects: 69
Study 23032867 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐ICD
Number of subjects: 69
Study 23032867 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐ICD and Conventional ICD
Number of subjects: 69
Study 20500136 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural graded activity
Number of subjects: 200
Study 20500136 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 18476431 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangyanling plus Omeprazole
Number of subjects: 52
Study 18476431 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 52
Study 15836974 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga therapy
Number of subjects: 60
Study 15836974 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 60
Study 12900300 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263
Study 12900300 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study 10526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 2199
Study 10526822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study 8867561 — intervention group
Group type: EXPERIMENTAL
Intervention: Study nurse measurements (22/14 +/- 20/9 mm Hg)
Number of subjects: 64
Study 8867561 — intervention group
Group type: EXPERIMENTAL
Intervention: Study doctor measurements (27/12 +/- 20/10 mm Hg)
Number of subjects: 64
Study 8867561 — intervention group
Group type: EXPERIMENTAL
Intervention: Referring doctor measurements (19/11 +/- 18/10 mm Hg)
Number of subjects: 64
Study 8867561 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (>= 65 years)
Number of subjects: 64
Study 8867561 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (< 65 years)
Number of subjects: 64
Study 8867561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 64
Study 1898686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower range of PaCO2 (32-48 mm Hg)
Number of subjects: 25
Study 1898686 — intervention group
Group type: COMPARATOR
Intervention: Higher range of PaCO2 (50-71 mm Hg)
Number of subjects: 25
Study 6688025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 96
Study 6688025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.8 mg kg‐1
Number of subjects: 96
Study 6688025 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 96
Study 6688025 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 96
Study 30914216 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplement use
Number of subjects: 197761
Study 30914216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 197761
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 11+ B. pyrrocinia × Magnaporthe oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 32+ B. pyrrocinia × Magnaporthe oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: B. pyrrocinia × M. oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 11 × M. oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 32 × M. oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: M. oryzae
Number of subjects: 0
Study 31089999 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 11+ B. pyrrocinia
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated 32+ B. pyrrocinia
Number of subjects: 0
Study 31089999 — intervention group
Group type: EXPERIMENTAL
Intervention: B. pyrrocinia
Number of subjects: 0
Study 27839695 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session with attending orthopaedic surgeon
Number of subjects: 13
Study 27839695 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session with senior resident
Number of subjects: 13
Study 27839695 — intervention group
Group type: COMPARATOR
Intervention: Pre-educational session
Number of subjects: 13
Study 27839695 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-educational session
Number of subjects: 13
Study 26091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief negotiated interview plus an educational kit by the American Automobile Association and a list of Web‐based resources for older adult drivers
Number of subjects: 120
Study 26091325 — intervention group
Group type: EXPERIMENTAL
Intervention: American Automobile Association document and a list of Web‐based resources
Number of subjects: 120
Study 26091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Online referral sheet of the list of Web‐based resources only
Number of subjects: 120
Study 22965330 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 134
Study 22965330 — intervention group
Group type: COMPARATOR
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 134
Study 21550532 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Nutrition Planner (PNP)
Number of subjects: 307
Study 21550532 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no program)
Number of subjects: 307
Study 19549077 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 43)
Number of subjects: 83
Study 19549077 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (n = 40)
Number of subjects: 83
Study 19549077 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 83
Study 17805217 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 0
Study 17805217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15332578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (250‐500 mg) + Clopidogrel (300 mg prehospital, then 75 mg/day after TLT)
Number of subjects: 72
Study 15332578 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (250‐500 mg)
Number of subjects: 72
Study 10691156 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening (50-g glucose challenge test followed by 3-h 100-g OGTT if plasma glucose at 1 h was >= 7.8 mmol/l)
Number of subjects: 0
Study 10691156 — intervention group
Group type: COMPARATOR
Intervention: Risk factor-based screening (3-h 100-g OGTT at 32 weeks if any risk factor for GDM was present)
Number of subjects: 0
Study 10691156 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening
Number of subjects: 0
Study 9346458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline for low back pain and three bimonthly feedback reports on current use rates for lumbar spine imaging tests (x-rays, CT, MRI)
Number of subjects: 95
Study 9346458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guideline or feedback reports)
Number of subjects: 95
Study 1441870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (Group B)
Number of subjects: 29
Study 1441870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + epinephrine (Group BE)
Number of subjects: 29
Study 1441870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine (Group BC)
Number of subjects: 29
Study 3556892 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about otitis media
Number of subjects: 59